{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:49:29Z","timestamp":1790426969208,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.antiviral.2019.104574","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:11:56Z","timestamp":1565003516000},"page":"104574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na\u00efve subjects"],"prefix":"10.1016","volume":"170","author":[{"given":"Bin","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyappa","family":"Parvangada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia S.","family":"Svarovskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104574_bib1","first-page":"2872371","article-title":"Sofosbuvir-based therapy for genotype 4 HCV recurrence post-liver transplant treatment-experienced patients","volume":"2016","author":"Ajlan","year":"2016","journal-title":"Chin. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib2","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104574_bib3","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib4","series-title":"Resistance Analyses for Ledipasvir\/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or Are Post Liver Transplant (SOLAR-1 and -2 Studies) the International Liver Congress","author":"Charlton","year":"2016"},{"key":"10.1016\/j.antiviral.2019.104574_bib5","series-title":"46th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany","article-title":"Nucleotide inhibitor resistance selections using GT2a infectious virus: PSI-7851 and GS-6620 select for a novel resistance pathway including substitutions of M289V\/L followed by S282T","author":"Cheng","year":"2011"},{"key":"10.1016\/j.antiviral.2019.104574_bib6","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","article-title":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir","volume":"61","author":"Donaldson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104574_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4","volume":"63","author":"Doss","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib9","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","article-title":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues","volume":"50","author":"Dutartre","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib10","series-title":"21st International Symposium on Hepatitis C Virus and Related Viruses, Banff, Alberta, Canada","article-title":"Susceptibility of HCV genotype 1, 2, 3 and 4 baseline clinical isolates to sofosbuvir","author":"Dvory-Sobol","year":"2014"},{"key":"10.1016\/j.antiviral.2019.104574_bib11","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1128\/AAC.02815-14","article-title":"Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase","volume":"58","author":"Dvory-Sobol","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib12","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib13","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep4.1060","article-title":"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment","volume":"1","author":"Gane","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.antiviral.2019.104574_bib15","series-title":"Sofosbuvir\/velpatasvir in Combination with Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A Containing DAA Regimens: Results of the GS-US-342-1553 Study, International Liver Congress","author":"Gane","year":"2016"},{"key":"10.1016\/j.antiviral.2019.104574_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2013.11.007","article-title":"Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17474124.2017.1326817","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C","volume":"11","author":"Jackson","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 Weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib22","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1074\/jbc.M510195200","article-title":"The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture","volume":"281","author":"Klumpp","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.104574_bib23","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.104574_bib24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.coph.2008.09.007","article-title":"Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors","volume":"8","author":"Kwong","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2019.104574_bib25","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib26","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00399-10","article-title":"PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication","volume":"54","author":"Lam","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104574_bib28","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib29","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/hep.29130","article-title":"Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104574_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2006.03.045","article-title":"In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance","volume":"351","author":"Le Pogam","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104574_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2019.104574_bib32","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","article-title":"Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay","volume":"49","author":"Ludmerer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2004.11.024","article-title":"Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors","volume":"332","author":"Ma","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2019.104574_bib34","doi-asserted-by":"crossref","first-page":"49164","DOI":"10.1074\/jbc.M305041200","article-title":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro","volume":"278","author":"Migliaccio","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2019.104574_bib35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104574_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Naggie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib37","series-title":"The Phenotypic Detection of HCV Polymerase Inhibitor Resistant Subpopulations Is Dependent on Relative Resistance and Replication Capacity; IC95 and Slope Values Can Improve Detection","author":"Paquet","year":"2012"},{"key":"10.1016\/j.antiviral.2019.104574_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2012.09.033","article-title":"Development of robust hepatitis C virus genotype 4 subgenomic replicons","volume":"144","author":"Peng","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib39","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1053\/j.gastro.2018.02.017","article-title":"HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models","volume":"154","author":"Pham","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.antiviral.2019.104574_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104574_bib42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1053\/j.gastro.2016.07.013","article-title":"Robust HCV genotype 3a infectious cell culture system permits identification of escape variants with resistance to sofosbuvir","volume":"151","author":"Ramirez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib43","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/AAC.00289-10","article-title":"Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a","volume":"54","author":"Robinson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2012.11.018","article-title":"Sofosbuvir (GS-7977) plus peginterferon\/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial","volume":"58","author":"Rodriguez-Torres","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jac\/dkh319","article-title":"Non-nucleoside inhibitors of the HCV polymerase","volume":"54","author":"Sarisky","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib46","series-title":"64th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA","article-title":"Baseline and post-baseline resistance analyses of phase 2\/3 studies of ledipasvir\/sofosbuvir \u00b1 RBV","author":"Sarrazin","year":"2014"},{"key":"10.1016\/j.antiviral.2019.104574_bib47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","article-title":"Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir","volume":"151","author":"Sarrazin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2019.104574_bib48","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104574_bib49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2019.104574_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/095632020601700203","article-title":"Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication","volume":"17","author":"Stuyver","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib51","series-title":"63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA","article-title":"Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-Containing regimens in phase 2 studies","author":"Svarovskaia","year":"2012"},{"key":"10.1016\/j.antiviral.2019.104574_bib52","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104574_bib53","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","article-title":"L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions","volume":"213","author":"Svarovskaia","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104574_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/095632020501600403","article-title":"HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase","volume":"16","author":"Tomei","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2019.104574_bib55","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","article-title":"Clinical outcomes after transfusion-associated hepatitis C","volume":"332","author":"Tong","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104574_bib56","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/jit562","article-title":"In vivo emergence of a novel mutant L159F\/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir","volume":"209","author":"Tong","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104574_bib57","series-title":"63rd Annual Meeting of the American Association for theStudy of Liver Diseases, Boston, MA","author":"Tong","year":"2012"},{"key":"10.1016\/j.antiviral.2019.104574_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jhep.2016.11.022","article-title":"Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir\/sofosbuvir","volume":"66","author":"Wyles","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2019.104574_bib60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.104574_bib61","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219302827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219302827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:32Z","timestamp":1759062692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219302827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":61,"alternative-id":["S0166354219302827"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104574","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-na\u00efve subjects","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104574"}}